Imilecleucel-T

Drug Profile

Imilecleucel-T

Alternative Names: Autologous T cell vaccine - Acer Therapeutics; Tcelna; Tovaxin®

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opexa Therapeutics
  • Developer Acer Therapeutics
  • Class Immunotherapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 19 Sep 2017 Acer Therapeutics merged with Opexa Therapeutics and the combined company has been named as Acer Therapeutics
  • 01 Oct 2016 Opexa Therapeutics completes the phase IIb Abili-T trial for secondary progressive Multiple sclerosis in USA and Canada (NCT01684761)
  • 06 Oct 2015 Four additional key patents issued to Opexa Therapeutics in Europe (Patent nos. 1 546 719,, 2 420 833 and 2 363 710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top